Increasing evidence exists that LYRIC/AEG-1 may act as an oncogene and promote tumourigenesis, chemoresistance and metastases (Brown and Ruoslahti, 2004; Emdad et al., 2006; Kikuno et al., 2007; Ash et al., 2008; Li et al., 2008; Sarkar et al., 2008; Hu et al., 2009; Kwong and Chin, 2009; Thirkettle et al., 2009) . LYRIC/ AEG-1 is reported to be regulated by HA-RAS and c-myc (Lee et al., 2006) , to suppress activators of apoptosis such as FOXO3a (Kikuno et al., 2007) , and to activate nuclear factor-kB which regulates the expression of cell adhesion molecules implicated in cancer progression and metastasis . Recently, it has been shown that LYRIC/AEG-1 is overexpressed in breast and prostate tumourigenesis (Li et al., 2008; Hu et al., 2009; Thirkettle et al., 2009) . We have shown that in benign prostate tissue LYRIC/ AEG-1 is localized predominantly in the nucleus and that loss of nuclear LYRIC/AEG-1 in cancer results in poor survival (Thirkettle et al., 2009) . However, little is known about LYRIC/AEG-1 interacting partners, in particular, those that reside within the nucleus.
To identify LYRIC/AEG-1 binding proteins, a truncated form of LYRIC/AEG-1, amino acids 73-582 (aa73-582) , lacking the N terminus and the leucine motif was used as bait in a yeast two-hybrid screen (Figures 1a and b) . A fragment of PLZF (aa322-528) was confirmed as an interacting partner of LYRIC/ AEG-1 through a b-galactosidase assay ( Figure 1b ). PLZF is a transcriptional repressor associated with growth suppression and apoptosis (Shaknovich et al., 1998; Bernardo et al., 2007) , regulating many genes including c-myc Bernardo et al., 2007) . PLZF contains a BTB/POZ domain at the N terminus amino acids 34-96 (aa34-96) , an RD2 domain (aa200-300) and 9 DNA-binding zinc fingers at the C terminus (aa404-652; Figure 1 ). PLZF SUMOylation is essential for its repressive activity (Chao et al., 2007) with lysine 242 acting as the master regulator of PLZF SUMOylation. Modification of this specific residue is essential for transcriptional repression of specific target genes by PLZF (Kang et al., 2003) through the recruitment of repressor complexes containing NCoR, SMRT, mSin3a and histone deacetylases (HDACs) via the BTB/ POZ domain (Kelly and Daniel, 2006) . There is evidence of a role for PLZF in prostate cancer (Jiang and Wang, 2004; Kikugawa et al., 2006) . Prostate cancer is dependent on the action of androgens, and PLZF has been shown to be an androgen-responsive gene (Jiang and Wang, 2004) . LYRIC/AEG-1 is upregulated in response to androgens (Waghray et al., 2001) .
In the LYRIC/AEG-1 interacting region identified by the yeast two-hybrid lies the C terminal of the RD2 domain and includes the first two zinc fingers. This interaction was confirmed by immunoprecipitating endogenous protein from KG1 cells over the background level of interaction detected in the control lane (Figure 1b) . HeLa cells cotransfected with GFP-LYRIC/AEG-1 and PLZF-V5 and analysed using LYRIC/AEG-1 relieves PLZF-mediated repression HJ Thirkettle et al confocal microscopy showed both proteins colocalize in a proportion of the punctate nuclear dots (Figure 1b) . Three LYRIC/AEG-1 constructs (aa1-285, aa286-486 and aa487-582; Figure 1a ) were used to define the interaction with PLZF ( Figure 1c ). Each of these constructs contains a lysine-rich region previously shown to regulate LYRIC/AEG-1 nuclear import (Thirkettle et al., 2009) . By immunoprecipitating the GFP-tagged LYRIC/AEG-1 constructs, we detected an interaction between the N-and C termini of LYRIC/ AEG-1 and PLZF. No interaction was detected between PLZF and the central region of LYRIC/AEG-1 (aa286-486), which is known to bind ubiquitin (Thirkettle et al., 2009 ; Figure 1c ). Previously characterized PLZF constructs (Chao et al., 2007) were tagged with V5 and used to define the domains that interact with LYRIC/AEG-1 ( Figure 1a ). The region bound most strongly by LYRIC was identified as the RD2 domain containing construct (aa121-456; Figure 1c ). This supported the results obtained from the yeast two-hybrid screen, which identified aa322-528 as the interacting region ( Figure 1a ). Using these data, we deduced that PLZF aa322-456 was necessary for the interaction with LYRIC/AEG-1. A construct comprised of this domain and a smaller construct of PLZF (aa322-404) lacking the first zinc fingers of PLZF was used to confirm the minimal LYRIC-interacting domain. Using immunoprecipitation, we showed that aa322-404 were sufficient to interact with LYRIC/AEG-1 (Figure 1c ). This region of PLZF contains two of the three lysine residues modified by SUMO required for PLZF activation (K387 and K396; Chao et al., 2007) . When the key lysine residue for PLZF SUMOylation was mutated (K242R), LYRIC/AEG-1 was no longer able to interact with PLZF (Figure 1d ), suggesting that LYRIC/AEG-1 only interacts with the active form of PLZF.
As LYRIC localization has been shown to be dynamic and alter during cancer progression, we investigated if the LYRIC/AEG-1-PLZF interaction occurred in the nucleus or the cytoplasm (Thirkettle et al., 2009) . HeLa cells cotransfected with GFP-LYRIC/AEG-1 and analysed using confocal microscopy showed LYRIC/AEG-1 throughout the cytoplasm (Figure 2 ). PLZF has been well characterized as a component of nuclear bodies containing PML, SP100 and SUMO (Kamitani et al., 1998; Seeler and Dejean, 1999) . PLZF overexpression leads to an increase in number of LYRIC/AEG-1 nuclear dots (Figure 1b , right panel compared to Figure 2 , top panel), although not all colocalized with PLZF. LYRIC/AEG-1 nucleoplasmic foci have previously been described, although not characterized, in NIH3T3 cells (Sutherland et al., 2004) . We showed that LYRIC/AEG-1/PLZF containing nuclear dots colocalize with only a few PML and SP100 foci, and with almost all SUMO and coilin foci; although previous work has suggested LYRIC/AEG-1 nucleoplasmic foci did not colocalize with Cajal bodies (Figure 2 ). LYRIC/AEG-1/PLZF nuclear dots colocalized with a very small number of RNA polymerase II foci, a marker of transcriptional activation. Most LYRIC/ AEG-1/PLZF nuclear dots were consistently localized to regions of the nucleus lacking any RNA polymerase II staining (Figure 2 ). This suggests that LYRIC/AEG-1 is unlikely to be involved with sites of transcriptional activation.
PLZF exerts its repressive function via interactions with HDAC1 and HDAC4 (David et al., 1998; Chauchereau et al., 2004) . PLZF and HDACs colocalize in nuclear speckles and also colocalize with LYRIC/ AEG-1/PLZF containing nuclear bodies ( Figure 3a) . As previously reported for LYRIC, both LYRIC and PLZF also colocalize with the nucleolar marker fibrillarin (Thirkettle et al., 2009) . When HDAC1 and HDAC4 were immunoprecipitated from COS7 cells cotransfected with PLZF-V5 and GFP-LYRIC/AEG-1, the presence of overexpressed LYRIC/AEG-1 increased b-Galactosidase assay confirms the interaction between PLZF and LYRIC/AEG-1 (left panel) PLZF well circled in black. Endogenous PLZF was immunoprecipitated (IP'd) using an anti-PLZF antibody (Calbiochem, Nottingham, UK) from 1 mg of KG1 protein lysate made as described (Whitaker et al., 2007; central panel) . 1%: input; C: IP control; IP: IP. Western blots were probed for LYRIC/AEG-1 (Thirkettle et al., 2009) and PLZF. Blots were visualized with ECL plus. Slight differences in PLZF molecular weight occur as a result of different salt concentrations in the samples. HeLa cells were grown and fixed on coverslips as described (Whitaker et al., 2007) following transfection with GFP-LYRIC/AEG-1 and PLZF-V5 using NanoJuice (Novagen, Nottingham, UK; right panel). Cells were probed with an anti-V5 antibody (Abcam, Cambridge, UK) and Alexafluor 594 (Molecular Probes, Paisley, UK) and mounted with 46-diamidino-2-phenylindole (DAPI). GFP-LYRIC/AEG-1 (green), PLZF (red) and DAPI (blue). Images were obtained using a Nikon Eclipse confocal microscope using a Â 100 objective. Scale bars represent 10 mm. LYRIC/AEG-1/PLZF nuclear bodies are indicated with white arrowheads. (c) Defining the LYRIC/AEG-1/PLZF interacting domains. COS7 cells were transfected with PLZF-V5 and GFP-wtLYRIC/AEG-1 or GFP-LYRIC/AEG-1 domain constructs using FuGENE 6 (Roche, Welwyn, Herts, UK; left panel). LYRIC was IP'd from 1 mg of lysate using an anti-GFP antibody (Abcam). Western blots were probed for V5 to detect PLZF. The band at 30 kDa is thought to be non-specific binding. GFP alone was used as a control. COS7 cells were transfected with GFP-LYRIC/AEG-1 and PLZF-V5 domain constructs (central panel). PLZF was IP'd as before using an anti-V5 antibody. Western blots were probed for GFP to detect LYRIC/AEG-1. The band at 50 kDa represents immunoglobulin G (IgG). Minimal PLZF-V5 interaction domains were transfected into COS7 cells and IP performed as before (right panel (Figure 3b ). This may reflect the ability of LYRIC/AEG-1 to sequester PLZF and different classes of HDACs to nuclear speckles.
Having shown that LYRIC/AEG-1 and PLZF interact and colocalize within nuclear bodies, we investigated the effect of LYRIC/AEG-1 on PLZF function using the PLZF reporter construct (Ball et al., 1999) . PLZF repressed reporter activity by 50% and the addition of LYRIC/AEG-1 significantly increased the level of luciferase activity in a dose-dependent manner (Figure 4a ; P ¼ 0.001). This suggests that LYRIC/ (Figure 1b) . HeLa cells were also stained using anti-PML (Sigma, Gillingham, Dorset, UK), anti-SP100 (Chemicon, Watford, Herts, UK), anti-coilin (Carvalho et al., 1999) and anti-SUMO (Zymed, California, CA, USA; all red). LYRIC/AEG-1 (green), 46-diamidino-2-phenylindole (DAPI; blue). Arrows indicate foci. All scale bars equal 10 mm. AEG-1 can reduce PLZF-mediated repression. We used quantitative real-time PCR to investigate the effect of LYRIC/AEG-1 on the mRNA levels of the PLZF target gene c-myc. When LYRIC/AEG-1 was overexpressed alongside PLZF the transcript level of c-myc significantly increased 3.5-fold over empty vector (P ¼ 0.03).
Others have suggested that LYRIC/AEG-1 exerts its effect by modulating protein levels (Ash et al., 2008) . We used western analysis of LNCaP cell lines transfected with empty vector, PLZF and GFP-LYRIC/AEG-1 constructs, to determine if LYRIC/AEG-1 was altering the expression of PLZF. There was no obvious change To determine how LYRIC/AEG-1 reduced PLZFmediated repression, we performed a chromatin immunoprecipitation (ChIP) assay using a PLZF antibody. The immunoprecipitated chromatin was assessed by PCR using primers against the c-myc promoter . Overexpression of LYRIC/AEG-1 decreased the amount of endogenous PLZF at the c-myc promoter (Figure 4d ). When PLZF and LYRIC/AEG-1 were cooverexpressed, the amount of PLZF bound to the c-myc promoter was decreased further. There was no effect on PLZF recruitment to the negative control gene, the Bcl-6 promoter .
In this study we have shown that nuclear LYRIC/ AEG-1 interacts with SUMOylated PLZF and localizes with PLZF repressor machinery within nuclear bodies. Overexpressed LYRIC/AEG-1 reduces PLZF-mediated repression by abrogating the ability of PLZF to bind DNA, perhaps by sequestering PLZF to nuclear bodies. LYRIC/AEG-1 has been shown to be overexpressed during tumourigenesis (Li et al., 2008; Hu et al., 2009; Thirkettle et al., 2009 ) and our results suggest that this may lead to a reduction in PLZF-mediated repression. This would increase oncogene expression such as c-myc and a decrease in genes involved in apoptosis (Bernardo et al., 2007) (Figure 4d ). C-myc has been shown to bind the promoter region of LYRIC/AEG-1 and regulate its expression (Lee et al., 2006) . When LYRIC/AEG-1 expression is tightly regulated in benign tissue, PLZF may repress gene expression; however, during tumourigenesis LYRIC/AEG-1 levels increase, potentially resulting in a reduction of PLZF-mediated repression. Our data provide a nuclear function for LYRIC/AEG-1 and a mechanism for its role as an oncogene. Its ability to block PLZF repression may provide a mechanism for cells to evade apoptosis and increase cell growth during tumourigenesis.
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